港股異動 | 上海醫藥(2607.HK)跌5.45% 向控股股東及雲南白藥非公開發行約8.53億股
格隆匯4月7日 | 上海醫藥(2607.HK)跌5.45%,報13.88港元,總市值394億港元。該公司今日發佈公吿,公司向公司控股股東上海上實的全資子公司上海潭東企業諮詢服務有限公司、戰略投資者雲南白藥集團股份有限公司分別非公開發行約1.87億股、6.66億股A股,合計約8.53億股,發行價格為16.39 元/股,募集資金總額為約人民幣139.75億元,募集資金淨額為約人民幣139.32億元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.